Drug Profile
Research programme: anti-influenza antibodies - XBiotech
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator XBiotech
- Class Antibodies
- Mechanism of Action Immunomodulators; Influenza virus haemagglutinin glycoprotein inhibitors; Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Parenteral)
- 09 Nov 2018 Preclinical trials in Influenza virus infections in USA (Parenteral) (XBiotech Pipeline)